Cardiometabolic wins among highlights in BioCentury’s latest Clinical Report

Advances in some of the most challenging indications, including MASH, depression and heart failure, were the value-drivers during a two-week period when the majority of clinical results were positive, yet mostly failed to move stocks.

One of the companies that did see a share price gain was  Akero Therapeutics Inc. (NASDAQ:AKRO), whose efruxifermin, a treatment for metabolic-associated nonalcoholic steatohepatitis (MASH; formerly NASH), became the first therapy to show a meaningful reversal of cirrhosis, an achievement that was once thought to be impossible. The Phase IIb data not only led to a near doubling of Akero’s value, but also drove up shares of another company developing an FGF21 therapy for the indication. ...